Ascelia Pharma Announces Organizational Changes and a Reduced Cost Base
Ascelia Pharma (STO:ACE), a biotech company focused on improving the lives of people with rare cancer conditions, today announces that CFO Anton Hansson will be leaving the Company. In connection with this change and cost reduction initiatives, Ascelia Pharma is reducing its cost base while focusing on the path forward for Orviglance®. The changes support alignment of resources with Ascelia Pharma's current priorities, including regulatory...
Read more









